Every biotech comeback story has a point where optimism and skepticism clash so sharply that even seasoned traders hesitate. That moment came this week in a very noticeable way for Moderna. On August 21, the company’s stock, which is traded under MRNA on the Nasdaq, closed at $145.13, up almost 9% in a single session and capping a week in which shares had risen about 70% above Wall Street consensus estimates. The speed of the reversal is nearly overwhelming to anyone who watched this stock crawl along its 52-week low of $22.28 just last November.
In a nutshell, cancer is the catalyst. The results of late-stage trials for the customized mRNA-based melanoma vaccine that Moderna and its partner Merck are working on appear to be remarkable enough to significantly alter market sentiment. The data was described as a possible breakthrough in reports from analysts at Mizuho and William Blair. The question of whether “potential” will eventually turn into “definitive” is still up for debate, but for the time being, the market appears willing to ignore it.
This rally has a strong emotional undertone that is difficult to ignore. During the COVID-19 pandemic, Moderna built its reputation on mRNA technology. However, it spent years witnessing that reputation crumble due to declining vaccine demand, declining revenue, and a stock that lost over 85% of its value between peak and trough. The 52-week low subtly but effectively conveys that narrative. $22.28 was a painful number for long-term shareholders.
The background is what makes this surge unique. The business isn’t making money. Its net margin is significantly negative at -141%, and its trailing twelve-month EPS is negative at $7.98. Revenue for the second quarter of 2026 was $145 million, a decrease of more than 35% annually.
These are not the numbers of a business that, according to conventional wisdom, ought to have a market capitalization of about $58 billion. However, it appears that investors are placing their bets not on Moderna’s current state but rather on its potential future if this cancer vaccine narrative is validated.
This has a historical parallel that is noteworthy. Before Keytruda became well-known in oncology circles, Merck was viewed with suspicion in some market segments. Many investors considered personalized cancer treatments to be speculative. Not too long ago, the notion that an mRNA vaccine could be customized to each patient’s unique tumor profile and truly yield significant clinical results was still only a pipe dream. It seems more realistic now. The next thing to watch is whether Moderna can make money off of that reality.
Notably, JPMorgan kept its sell rating in place on August 21 despite the stock’s 13% increase. High-conviction biotech decisions frequently exhibit this kind of discrepancy between analyst caution and market momentum. Additionally, it serves as a reminder that these rallies can end just as quickly. As of late July, short interest remained at almost 14% of the float, which is a significant figure and probably contributed to the squeeze dynamic that Barron’s called “historic.”
This move has been compressed, as evidenced by the 52-week high of $176.66, which was reached just days ago on August 19. Moderna’s stock price increased by more than 690% between that November low and the most recent high. It takes more than just fundamentals to make that kind of move. It occurs when a narrative changes, when trial data is unexpected, and when a sufficient number of short sellers are caught off guard at the same time.
It’s really unclear what will happen next. Early November is when Moderna is expected to release its next earnings report. Every clinical update, analyst note, and FDA signal will have significant weight between now and then. The stock is erratic; the real daily fluctuations are understated by a beta of 1.02. In a single trading day on August 21, the range was between $132.42 and $159.47, a spread of almost $27.
Some observers believe that Moderna may be moving into a new phase, one centered around oncology and the wider application of mRNA science rather than the pandemic-era company or the faltering post-COVID narrative. It remains to be seen if that emotion translates into long-lasting value. The Moderna stock price is currently speaking for itself.
